Biome Australia (BIO) Status Update summary

Leadership and board strategy

• New chair brings 40 years of healthcare and private equity experience, aiming to support domestic and international growth.

• Board rejuvenation is underway, with plans to add members aligned with strategic goals.

• Focus on supporting management and resourcing as growth opportunities arise.

Financial and trading update

• FY25 is set to close with a record quarter, driven by strong Q4 and seasonal demand.

• Growth rate is over 50%, outpacing category averages by more than 10 times.

• First full year of profit expected, positioning for sustainable growth into FY26 and beyond.

• Positive long-term outlook, with confidence in continued operational execution and new investor interest.

Product and innovation pipeline

• Product range expanding to 20 SKUs, with a long-term target of 25-30, focusing on clinically backed, first-to-market launches.

• New sub-brand, Activated Therapeutics, introduces non-probiotic products targeting gut health and adjacent categories.

• Practitioner-only products to be launched, supported by strong retail and pharmacy partnerships.

• Ongoing development of proprietary strain BMB18, with late-stage planning for clinical studies and integration into products by FY26-27.